top of page
Human Primary Lymphoma Cells
Human primary lymphoma cells are cryopreserved malignant lymphocytes obtained from biopsies or peripheral blood of patients diagnosed with B- or T-cell lymphomas. Because they retain the original tumor’s genetic, phenotypic and functional characteristics, they provide a clinically relevant model for drug screening, biomarker discovery and PDX-model establishment—far surpassing immortalized lines in translational value.

Human Primary Lymphoma Cells

$900.00Price
    • 1 mln cells/vial
    • Post-thaw viability - ≥ 70%
    • Morphology - large blast-like lymphoid cells; high nuclear/cytoplasmic ratio
    • Purity - ≥ 90 % CD19⁺ for B-cell lymphoma or ≥ 90 % CD3⁺ for T-cell lymphoma 
    • Growth Characteristics - typically non-adherent, suspension culture, doubling time ≈ 36–72 h

    • Drug screening and sensitivity testing

    • Molecular profiling (RNA-seq, WES)

    • Co-culture and tumor microenvironment studies

    • Immunotherapy evaluation (e.g., CAR-T, antibodies)

    • Biomarker discovery and validation

    • Patient-derived xenograft (PDX) model generation

    • Functional assays (viability, apoptosis, proliferation

bottom of page